Get the Stockscreener App
19.36
3.20%
0.60
Lb Pharmaceuticals Inc stock is traded at $19.36, with a volume of 162.42K.
It is up +3.20% in the last 24 hours and up +17.33% over the past month.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
See More
Previous Close:
$18.76
Open:
$18.52
24h Volume:
162.42K
Relative Volume:
1.25
Market Cap:
$489.79M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+17.12%
1M Performance:
+17.33%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$18.22
$19.69
1-Week Range:
$16.12
$19.69
52-Week Range:
$13.36
$19.69
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
19.36 | 474.61M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LB Pharmaceuticals Inc: Target Price Consensus and Analysts Recommendations | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Revenue and Earnings Analysts Forecasts Revisions | LBRX | US50180M1080 - MarketScreener
LB Pharmaceuticals Inc: Dividend historical data and projections - MarketScreener
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
LB Pharmaceuticals Appoints New Chief Commercial Officer - MSN
LB Pharmaceuticals amends lease to expand New York office space By Investing.com - Investing.com Australia
LB Pharmaceuticals Expands Lease at One Penn Plaza - TipRanks
LB Pharmaceuticals amends lease to expand New York office space - Investing.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event | LBRX SEC FilingForm 8-K - Stock Titan
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer - Investing.com Nigeria
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals names Kaya Pai Panandiker as CCO - The Pharma Letter
LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer By Investing.com - Investing.com South Africa
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - The Manila Times
LB Pharmaceuticals, Inc Announces Appointment of Kaya Pai Panandiker as Chief Commercial Officer - MarketScreener
LB Pharmaceuticals - Nasdaq
LB Pharmaceuticals Reports Strong Q3 and Strategic Progress - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot - theheraldreview.com
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference - The Manila Times
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 - Investing.com Nigeria
LB Pharmaceuticals reports Q3 results, plans Phase 3 trial for LB-102 By Investing.com - Investing.com South Africa
LBRX: IPO raised $327.8M; LB-102 advances with strong data; Q3 net loss narrows to $3.6M - TradingView
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates - The Manila Times
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
LB Pharmaceuticals, Inc. (LBRX) Stock News Today - TipRanks
LB Pharmaceuticals Inc Rings the Closing Bell - Nasdaq
LB Pharmaceuticals Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement - Bloomberg.com
LB Pharmaceuticals Inc (LBRX) Recent Insider Transactions - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Latest Press Releases & Corporate News - Yahoo
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo! Finance Australia
Anna Eramo Net Worth (2025) - GuruFocus
Rebecca Luse Net Worth (2025) - GuruFocus
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
There is no financial data for Lb Pharmaceuticals Inc (LBRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):